No concomitant occurrence of the N-ras and p53 gene mutations in myelodysplastic syndromes

Leukemia

Volumn 11, Issue 6, 1997, Pages 863-865

  Mitani, K ^a   Hangaishi, A ^a   Imamura, N ^b   Miyagawa, K ^b   Ogawa, S ^a   Kanda, Y ^a   Yazak, Y ^a   Hirai, H ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b HIROSHIMA UNIVERSITY   (Japan)

Author keywords

Gene mutation; Myelodysplastic syndrome; N ras; p53; SSCP

Indexed keywords

PROTEIN P53;

ADULT; ARTICLE; BLAST CELL; BONE MARROW CELL; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DNA DETERMINATION; DNA SEQUENCE; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; LEUKEMIA; MALE; MYELODYSPLASTIC SYNDROME; ONCOGENE N RAS; PRIORITY JOURNAL; REFRACTORY ANEMIA; RESTRICTION MAPPING; SINGLE STRAND CONFORMATION POLYMORPHISM; TUMOR SUPPRESSOR GENE;

EID: 0030986849     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2400666     Document Type: Article

References (12)

1. Hirai H, Kobayashi Y, Mano H, Hagiwara K, Maru Y, Omine M, Mizoguchi H, Nishida J, Takaku F. A point mutation at codon 13 of the N-ras oncogene in myelodysplastic syndrome. Nature 1987; 327: 430-432.
2. Hirai H, Okada M, Mizoguchi H, Mano H, Kobayashi Y, Nishida J, Takaku F. Relationship between an activated N-ras oncogene and chromosomal abnormality during leukemic progression from myelodysplastic syndrome. Blood 1988; 71: 256-258.
3. Yunis JJ, Boot AJ, Mayer MG, Bos JL. Mechanisms of ras mutation in myelodysplastic syndrome. Oncogene 1989; 4: 609-614.
4. van Kamp H, de Pijper C, Verlaan-de Vries M, Bos JL, Leeksma CHW, Kerkhofs H, Willemze R, Fibbe WE, Landegent JE. Longitudinal analysis of point mutations of the N-ras proto-oncogene in patients with myelodysplasia using archived blood smears. Blood 1992; 79: 1266-1270.
5. Raquette RL, Landaw EM, Pierre RV, Kahan J, Lubbert M, Lazcano O, Isaac G, McCormick F, Koeffler HP. N-ras mutations are associated with poor prognosis and increased risk of leukemia in myelodysplastic syndrome. Blood 1993; 82: 590-599.
6. Nakagawa T, Saitoh S, Imoto S, Itoh M, Tsutsumi M, Hikiji K, Nakamura S, Matozaki R, Ogawa R, Nakao Y. Multiple point mutation of N-ras and K-ras oncogenes in myelodysplastic syndrome and acute myelogenous leukemia. Oncology 1992; 49: 114-122.
7. Sugimoto K, Hirano N, Toyoshima H, Chiba S, Mano H, Takaku F, Yazaki Y, Hirai H. Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS-derived leukemia. Blood 1993; 81: 3022-3026.
8. Adamson DJA, Dawson AA, Bennett B, King DJ, Haites NE. p53 mutation in the myelodysplastic syndromes. Br J Haematol 1995; 89: 61-66.
9. Wattel E, Preudhomme C, Hecquet B, Vanrumbeke M, Quesnel B, Dervite I, Morel P, Fenaux P. p53 mutations are associated with resistance to chemotherapy and short survival in hematologic malignancies. Blood 1994; 84: 3148-3157.
10. Mitani K, Kanda Y, Ogawa S, Tanaka T, Inazawa J, Yazaki Y, Hirai H. Cloning of several species of MLL/MEN chimeric cDNAs in myeloid leukemia with t(11;19)(q23;p13.1) translocation. Blood 1995; 85: 2017-2024.
11. Lubbert M, Mirro J Jr, Kitchingman G, McCormick F, Mertelsmann R, Herrmann F, Koeffler HP. Prevalence of N-ras mutations in children with myelodysplastic syndromes and acute myeloid leukemia. Oncogene 1992; 7: 263-268.
12. Buhler-Leclerc M, Gratwohl A, Senn H-P. Occurrence of point mutations in p53 gene is not increased in patients with acute myeloid leukaemia carrying an activating N-ras mutation. Br J Haematol 1993; 84: 443-450.